Liquid formulation of Vimpat relaunched

The antiepileptic Vimpat (lacosamide) has been relaunched by UCB Pharma and is now formulated as a lower strength syrup.

Vimpat syrup is unsuitable for patients with phenylketonuria
Vimpat syrup is unsuitable for patients with phenylketonuria

Vimpat (lacosamide) 10mg/ml syrup is indicated for the adjunctive treatment of partial onset-seizures with or without secondary generalisation in adults and children 16 years of age and older. The 10mg/ml syrup replaces the previous 15mg/ml formulation, which was recalled in 2011.

View Vimpat Syrup drug record

Further information: UCB Pharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...